• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by MeiraGTx Holdings plc

    4/24/26 4:46:50 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 8)


    MeiraGTx Holdings plc

    (Name of Issuer)


    Ordinary Shares, nominal value $0.00003881 per share

    (Title of Class of Securities)




    G59665102

    (CUSIP Number)
    Alexander Rakitin
    Perceptive Advisors LLC, 51 Astor Place, 10th Floor
    New York, NY, 10003
    (646) 205-5345

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/17/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    G59665102


    1 Name of reporting person

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    11,742,117.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    11,742,117.00
    11Aggregate amount beneficially owned by each reporting person

    11,742,117.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.6 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    CUSIP Number(s):
    G59665102


    1 Name of reporting person

    Joseph Edelman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    11,742,117.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    11,742,117.00
    11Aggregate amount beneficially owned by each reporting person

    11,742,117.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.6 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    G59665102


    1 Name of reporting person

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    11,742,117.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    11,742,117.00
    11Aggregate amount beneficially owned by each reporting person

    11,742,117.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.6 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value $0.00003881 per share
    (b)Name of Issuer:

    MeiraGTx Holdings plc
    (c)Address of Issuer's Principal Executive Offices:

    655 Third Avenue, Suite 1115, New York, NEW YORK , 10017.
    Item 5.Interest in Securities of the Issuer
    (a)
    Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 8 to Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 92,557,237 outstanding Ordinary Shares, as reported by the Issuer in its Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on April 16, 2026, and give effect to (i) the exercise of Warrants (as defined below) for 700,000 Ordinary Shares as if such Warrants had been exercised, (ii) the exercise of vested stock options for 115,459 Ordinary Shares, and (iii) the settlement of vested deferred share units for an aggregate of 140,000 Ordinary Shares.
    (b)
    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. The Master Fund holds (i) stock options exercisable for a total of 15,459 Ordinary Shares, all of which are currently exercisable, and (ii) Warrants for 700,000 Ordinary Shares. Ellen Hukkelhoven, the Head of Investment Research of Perceptive, holds (i) stock options exercisable for a total of 100,000 Ordinary Shares, all of which are currently exercisable or become exercisable within 60 days, and (ii) 140,000 deferred share units, all of which have vested or will vest within 60 days. The Reporting Persons have rights to the stock options and deferred share units held by Ms. Hukkelhoven pursuant to a management fee offset.
    (c)
    The information set forth in Item 6 of this Amendment No. 8 is incorporated by reference to this Item 5(c). On April 17, 2026, the Master Fund purchased 555,555 Ordinary Shares at a price per share of $9.00 in the Issuer's underwritten offering. Except as described herein, none of the Reporting Persons has effected any transaction in the Ordinary Shares in the past 60 days.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of the Schedule 13D is amended and supplemented as follows: On March 25, 2026, the Issuer, Perceptive Credit Holdings III, L.P. ("Credit Fund III"), and the other parties to the Notes Purchase Agreement (as defined below) entered into Amendment No. 4 thereto (the "Notes Purchase Agreement Amendment") whereby, among other things, the exercise price of the Warrants was adjusted to $8.00 per share. On August 2, 2022, the Issuer, Credit Fund III and the other parties thereto entered into a senior secured financing arrangement (the "Financing Agreement") pursuant to which Credit Fund III and the other lenders party thereto agreed to lend to the Issuer an initial $75 million term loan and an additional $25 million term loan tranche to be made available at Credit Fund III's sole discretion. In connection with entering into the Financing Agreement, the Issuer issued to Credit Fund III (i) warrants exercisable for 400,000 Ordinary Shares at an exercise price of $15.00 per share and (ii) warrants exercisable for 300,000 Ordinary Shares at an exercise price of $20.00 per share (collectively, the "Warrants"). The Warrants are immediately exercisable and expire on August 2, 2027. On December 19, 2022, the Financing Agreement was converted into a Notes Purchase Agreement. Perceptive Credit Advisors LLC ("Perceptive Credit Advisors") serves as the investment advisor to Credit Fund III and as a relying advisor under Perceptive Advisors. Mr. Edelman is the managing member of Perceptive Credit Advisors. The foregoing description of the Warrants and the Notes Purchase Agreement Amendment is qualified in its entirety by reference to the full text of the Warrants and the Notes Purchase Agreement Amendment, copies of which are included as Exhibit 7 and Exhibit 8 hereto, respectively.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is amended and supplemented as follows: Exhibit 7 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022) Exhibit 8 Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates, dated March 25, 2026, by and among MeiraGTx Holdings plc, as issuer, the subsidiary guarantors and noteholders from time to time party thereto, and Perceptive Credit Holdings III, LP, as administrative agent and noteholder. (incorporated by reference to Exhibit 10.53 to the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026)

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:04/24/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:04/24/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:04/24/2026
    Get the next $MGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    11/24/2025$20.00Buy
    H.C. Wainwright
    10/21/2025$29.00Strong Buy
    Raymond James
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO & COO Giroux Richard gifted 7,000 units of Ordinary Shares, decreasing direct ownership by 0.72% to 964,530 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/28/26 9:04:10 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT & CEO Forbes Alexandria sold $568,540 worth of Ordinary Shares (62,000 units at $9.17) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,387,695 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/19/26 9:05:19 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Fleck Penny Renee

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/14/26 9:06:37 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    8/14/24 6:54:38 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MeiraGTx with a new price target

    H.C. Wainwright initiated coverage of MeiraGTx with a rating of Buy and set a new price target of $20.00

    11/24/25 8:18:26 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on MeiraGTx with a new price target

    Raymond James initiated coverage of MeiraGTx with a rating of Strong Buy and set a new price target of $29.00

    10/21/25 7:21:05 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

    Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

    7/31/24 6:30:53 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4). Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company's ordinary shares with an exercise price equal to $9.9

    5/14/26 4:30:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Reports First Quarter 2026 Financial and Operational Results

    Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2

    5/14/26 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

    LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx. The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its

    4/16/26 7:47:22 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    SEC Filings

    View All

    SEC Form 144 filed by MeiraGTx Holdings plc

    144 - MeiraGTx Holdings plc (0001735438) (Subject)

    5/19/26 9:03:54 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by MeiraGTx Holdings plc

    10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

    5/14/26 8:30:23 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MeiraGTx Holdings plc (0001735438) (Filer)

    5/14/26 8:06:12 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/12/24 9:40:33 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

    SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    8/14/24 7:21:27 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Landsdowne Labs Names Bryan Laulicht CEO

    Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    MeiraGTx Appoints Debra Yu, MD to Board of Directors

    LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

    4/27/22 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Financials

    Live finance-specific insights

    View All

    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

    Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP. "We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,"

    4/16/26 7:10:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohortsIncreases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 yearsAAV-hAQP1 was safe and well tolerated at each dose testedAAV-hAQP1 Data presentation webcast to be held today, April 16, 2026, at 8:00 a.m. ET LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment

    4/16/26 7:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

    - Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET. The

    4/14/26 8:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care